Advicenne (PA:ALDVI) — Market Cap & Net Worth
Market Cap & Net Worth: Advicenne (ALDVI)
Advicenne (PA:ALDVI) has a market capitalization of $20.93 Million (€17.90 Million) as of May 5, 2026. Listed on the PA stock exchange, this France-based company holds position #24866 globally and #406 in its home market, demonstrating a -5.09% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Advicenne's stock price €1.23 by its total outstanding shares 14551540 (14.55 Million). Analyse Advicenne cash conversion from operations to see how efficiently the company converts income to cash.
Advicenne Market Cap History: 2017 to 2026
Advicenne's market capitalization history from 2017 to 2026. Data shows change from $233.02 Million to $20.93 Million (-24.94% CAGR).
Advicenne Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Advicenne's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.74x
Advicenne's market cap is 6.74 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $233.02 Million | $806.30K | -$4.65 Million | 289.00x | N/A |
| 2018 | $158.67 Million | $1.19 Million | -$4.63 Million | 133.34x | N/A |
| 2019 | $147.00 Million | $2.00 Million | -$14.20 Million | 73.53x | N/A |
| 2020 | $167.04 Million | $2.06 Million | -$14.85 Million | 81.01x | N/A |
| 2021 | $159.02 Million | $2.69 Million | -$12.43 Million | 59.14x | N/A |
| 2022 | $76.34 Million | $2.40 Million | -$11.47 Million | 31.85x | N/A |
| 2023 | $45.25 Million | $4.46 Million | -$7.03 Million | 10.15x | N/A |
| 2024 | $33.51 Million | $4.97 Million | -$6.46 Million | 6.74x | N/A |
Competitor Companies of ALDVI by Market Capitalization
Companies near Advicenne in the global market cap rankings as of May 5, 2026.
Key companies related to Advicenne by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $109.06 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #357 globally with a market cap of $73.69 Billion USD.
- UCB SA (BR:UCB): Ranked #519 globally with a market cap of $50.85 Billion USD ( €43.50 Billion EUR).
- argenx NV ADR (NASDAQ:ARGX): Ranked #567 globally with a market cap of $45.97 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $109.06 Billion | $429.85 |
| #357 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.69 Billion | $709.21 |
| #519 | UCB SA | BR:UCB | $50.85 Billion | €228.50 |
| #567 | argenx NV ADR | NASDAQ:ARGX | $45.97 Billion | $787.95 |
Advicenne Historical Marketcap From 2017 to 2026
Between 2017 and today, Advicenne's market cap moved from $233.02 Million to $ 20.93 Million, with a yearly change of -24.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €20.93 Million | -28.90% |
| 2025 | €29.43 Million | -12.18% |
| 2024 | €33.51 Million | -25.94% |
| 2023 | €45.25 Million | -40.72% |
| 2022 | €76.34 Million | -52.00% |
| 2021 | €159.02 Million | -4.80% |
| 2020 | €167.04 Million | +13.64% |
| 2019 | €147.00 Million | -7.36% |
| 2018 | €158.67 Million | -31.91% |
| 2017 | €233.02 Million | -- |
End of Day Market Cap According to Different Sources
On May 5th, 2026 the market cap of Advicenne was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $20.93 Million USD |
| MoneyControl | $20.93 Million USD |
| MarketWatch | $20.93 Million USD |
| marketcap.company | $20.93 Million USD |
| Reuters | $20.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Advicenne
Advicenne S.A., a specialty pharmaceutical company, develops, commercializes, and markets treatments for rare renal diseases in France and internationally. It offers Sibnayal for the treatment of metabolic disorders, distal renal tubular acidosis, and cystinuria. The company also distributes Likozam, a formulation of clobazam for the treatment of short-term symptomatic of severe, disabling, or co… Read more